Daily Edition · Page 1

THE DAILY INDEX

Technology, AI, software, security, crypto and business

Across today’s newsletters

Today’s Index

SEC SAYS LIQUID STAKING DOESN'T RUN AFOUL OF SECURITIES LAWS

The SEC's Division of Corporation Finance clarified in a non-binding staff statement that liquid staking, where users deposit covered crypto assets to receive receipt tokens, does not require securities-law disclosures as long as the assets aren't part of an investment contract. With nearly $67 billion in TVL across protocols like Lido, Jito, and Rocket Pool, the market saw only muted price changes after the announcement. The guidance emphasizes that liquid staking providers act as agents without entrepreneurial or managerial efforts in staking decisions. By following this statement, industry participants should avoid enforcement actions under current securities laws.

ANTHROPIC UNVEILS MORE POWERFUL AI MODEL AHEAD OF RIVAL GPT-5 RELEASE

Anthropic's new model, Opus 4.1, is more capable at coding, research, and data analysis and better at fielding complex multistep problems than previous versions. It can better navigate large codebases and make more precise modifications to code. Opus 4.1 scores two percentage points higher than its predecessor on SWE-Bench Verified, a popular coding evaluation benchmark. Anthropic is currently finalizing a deal to raise as much as $5 billion in a new funding round at a valuation of $170 billion.

OPENAI'S NEW OPEN WEIGHT (APACHE 2) MODELS ARE REALLY GOOD

OpenAI's long-awaited open weight models have been released. The 120B model achieves near-party with OpenAI o4-mini on core reasoning benchmarks while running efficiently on a single 80 GB GPU. The 20B model delivers similar results to OpenAI o3-mini on common benchmarks and can run on edge devices with just 16 GB of memory. Both models are mixture-of-experts. It is likely that OpenAI now offers the best available open weights models.

OZEMPIC SHOWS ANTI-AGING EFFECTS IN FIRST CLINICAL TRIAL, REVERSING BIOLOGICAL AGE BY 3.1 YEARS

Ozempic demonstrated remarkable anti-agent effects in a randomized controlled trial involving 108 people with HIV-associated lipohypertrophy, a condition characterized by excess fat accumulation and accelerated cellular aging. The researchers used epigenetic clocks to assess biological aging and found that those on semaglutide became 3.1 years biologically younger on average by the end of the study. The anti-aging effects weren't uniform across all body systems - the most dramatic improvements occurred in the inflammatory system and brain. The researchers believe that the anti-aging properties of semaglutide stem from its effects on fat distribution and metabolic health.

FIRST EVIDENCE OF MICROPLASTIC MOBILIZATION IN A HUMAN SUBJECT – A SELF-EXPERIMENT

Microplastics are everywhere. Studies show that microplastic burden strongly correlates with negative health outcomes. This post presents an experimental protocol that tricks cells into releasing microplastics back into the blood, where they can be transported to the liver for biliary excretion or actively removed with plasma exchange. It involves using a compound derived from broccoli as a microplastics mobilizer.

TLDR IndexPage 1